Prothena Corporation plc (PRTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $419.01M
Last updated: Nov 17, 2026 at 11:06 AM ET
Prothena Corporation plc (PRTA) Stock Forecast
Analysts expect Prothena Corporation (PRTA) to earn $0.64 per share in the fiscal year ending Dec 31, 2026, on revenue of $80.19M. Of 7 analysts, 4 rate the stock Buy or Strong Buy, 2 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.43, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 57% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 28.6% |
| Buy | 2 | 28.6% |
| Hold | 2 | 28.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 14.3% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates fall 73.8%.
- Fiscal year ending Dec 31, 2026
- $0.64
- EPS consensus, revenue $80.19M
- Fiscal year ending Dec 31, 2027
- -$1.32
- EPS consensus, revenue $21.04M
- Next report
- Feb 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.64 | $0.64 to $0.64 | 1 | $80.19M | $52.70M to $107.71M | 7 |
| Dec 31, 2027 | -$1.32 | -$1.52 to -$1.11 | 2 | $21.04M | N/A | 7 |
Quarterly Estimates
The EPS consensus falls from -$0.09 for the quarter ending Dec 31, 2026 to -$0.41 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.38 to $0.79 | 8 | $15.10M | N/A | 8 |
| Mar 31, 2027 | -$0.41 | -$0.41 to -$0.41 | 1 | N/A | N/A | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1180.0% from $0.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.64 | N/A | N/A | N/A | $0.05 | +1180.0% |
| Fiscal year ending Dec 31, 2027 | -$1.32 | -$1.52 | -$1.52 | -$1.52 | -$1.31 | N/A |
| Quarter ending Mar 31, 2027 | -$0.41 | -$0.36 | -$0.36 | -$0.36 | -$0.36 | N/A |
Frequently Asked Questions About PRTA
What is the PRTA stock forecast?
Consensus analyst estimates put Prothena Corporation's EPS at $0.64 for the fiscal year ending Dec 31, 2026, on revenue of $80.19M. The consensus rating from 7 analysts is Buy.
How do analysts rate PRTA stock?
Of 7 analysts covering Prothena Corporation, 2 rate it Strong Buy, 2 Buy, 2 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PRTA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.64, with estimates from $0.64 to $0.64 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.32, with estimates from -$1.52 to -$1.11 from 2 analysts.
What revenue do analysts expect from Prothena Corporation next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $80.19M, with estimates from $52.70M to $107.71M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $21.04M.
How many analysts cover PRTA?
7 analysts rate Prothena Corporation stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
PRTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors